Standardized Procedure for Measurement of Nasal Potential Difference: An Outcome Measure in Multicenter Cystic Fibrosis Clinical Trials

Thomas A. Standaert, Louis Boitano, Julia Emerson, Laura J H Milgram, Michael W. Konstan, Janice Hunter, Pierre Yves Berclaz, Lois Brass, Pamela L. Zeitlin, Keith Hammond, Zoe Davies, Carla Foy, Peadar G. Noone, Michael R. Knowles

Research output: Contribution to journalArticle

Abstract

Patients with cystic fibrosis (CF) can be discriminated from healthy subjects by measurement of the nasal potential difference, which has become a useful outcome measure for therapies directed toward correcting defective electrolyte transport in CF. A standard operating procedure was developed by a CF Foundation clinical trials network, to be followed by all sites performing collaborative studies. Key variables in the measurement included type of voltmeter, exploring probe, reference electrodes, and solutions used to assess both sodium transport and chloride conductance. Eight sites submitted data on 3-8 normal and 4-5 CF subjects. Baseline voltage, an index of sodium transport, was -18.2±8.3 mV (mean±SD) for normals, and -45.3 ± 11.4 mV for CF patients. There was no CFTR- mediated chloride secretion in CF subjects, as evidenced by the lack of response to perfusion with zero chloride + beta agonist solutions (+3.2 ± 3.5 mV) vs. that in normals (-23.7 ± 10.2 mV). The standardized nasal potential difference measurement minimizes variability between operators and study sites. Valid and consistent results can be attained with trained operators and attention to technical details. These data demonstrate the procedure to be sufficient for multicenter studies in the CF Foundation network.

Original languageEnglish (US)
Pages (from-to)385-392
Number of pages8
JournalPediatric Pulmonology
Volume37
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

Nose
Cystic Fibrosis
Outcome Assessment (Health Care)
Clinical Trials
Chlorides
Sodium Chloride
Electrolytes
Multicenter Studies
Healthy Volunteers
Electrodes
Perfusion
Sodium

Keywords

  • Clinical trial
  • Cystic fibrosis
  • Epithelium
  • Multicenter
  • Nasal
  • Potential difference
  • SOP

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Standaert, T. A., Boitano, L., Emerson, J., Milgram, L. J. H., Konstan, M. W., Hunter, J., ... Knowles, M. R. (2004). Standardized Procedure for Measurement of Nasal Potential Difference: An Outcome Measure in Multicenter Cystic Fibrosis Clinical Trials. Pediatric Pulmonology, 37(5), 385-392. https://doi.org/10.1002/ppul.10448

Standardized Procedure for Measurement of Nasal Potential Difference : An Outcome Measure in Multicenter Cystic Fibrosis Clinical Trials. / Standaert, Thomas A.; Boitano, Louis; Emerson, Julia; Milgram, Laura J H; Konstan, Michael W.; Hunter, Janice; Berclaz, Pierre Yves; Brass, Lois; Zeitlin, Pamela L.; Hammond, Keith; Davies, Zoe; Foy, Carla; Noone, Peadar G.; Knowles, Michael R.

In: Pediatric Pulmonology, Vol. 37, No. 5, 05.2004, p. 385-392.

Research output: Contribution to journalArticle

Standaert, TA, Boitano, L, Emerson, J, Milgram, LJH, Konstan, MW, Hunter, J, Berclaz, PY, Brass, L, Zeitlin, PL, Hammond, K, Davies, Z, Foy, C, Noone, PG & Knowles, MR 2004, 'Standardized Procedure for Measurement of Nasal Potential Difference: An Outcome Measure in Multicenter Cystic Fibrosis Clinical Trials', Pediatric Pulmonology, vol. 37, no. 5, pp. 385-392. https://doi.org/10.1002/ppul.10448
Standaert, Thomas A. ; Boitano, Louis ; Emerson, Julia ; Milgram, Laura J H ; Konstan, Michael W. ; Hunter, Janice ; Berclaz, Pierre Yves ; Brass, Lois ; Zeitlin, Pamela L. ; Hammond, Keith ; Davies, Zoe ; Foy, Carla ; Noone, Peadar G. ; Knowles, Michael R. / Standardized Procedure for Measurement of Nasal Potential Difference : An Outcome Measure in Multicenter Cystic Fibrosis Clinical Trials. In: Pediatric Pulmonology. 2004 ; Vol. 37, No. 5. pp. 385-392.
@article{e0360f0149a547e0bc07c615bc3dad56,
title = "Standardized Procedure for Measurement of Nasal Potential Difference: An Outcome Measure in Multicenter Cystic Fibrosis Clinical Trials",
abstract = "Patients with cystic fibrosis (CF) can be discriminated from healthy subjects by measurement of the nasal potential difference, which has become a useful outcome measure for therapies directed toward correcting defective electrolyte transport in CF. A standard operating procedure was developed by a CF Foundation clinical trials network, to be followed by all sites performing collaborative studies. Key variables in the measurement included type of voltmeter, exploring probe, reference electrodes, and solutions used to assess both sodium transport and chloride conductance. Eight sites submitted data on 3-8 normal and 4-5 CF subjects. Baseline voltage, an index of sodium transport, was -18.2±8.3 mV (mean±SD) for normals, and -45.3 ± 11.4 mV for CF patients. There was no CFTR- mediated chloride secretion in CF subjects, as evidenced by the lack of response to perfusion with zero chloride + beta agonist solutions (+3.2 ± 3.5 mV) vs. that in normals (-23.7 ± 10.2 mV). The standardized nasal potential difference measurement minimizes variability between operators and study sites. Valid and consistent results can be attained with trained operators and attention to technical details. These data demonstrate the procedure to be sufficient for multicenter studies in the CF Foundation network.",
keywords = "Clinical trial, Cystic fibrosis, Epithelium, Multicenter, Nasal, Potential difference, SOP",
author = "Standaert, {Thomas A.} and Louis Boitano and Julia Emerson and Milgram, {Laura J H} and Konstan, {Michael W.} and Janice Hunter and Berclaz, {Pierre Yves} and Lois Brass and Zeitlin, {Pamela L.} and Keith Hammond and Zoe Davies and Carla Foy and Noone, {Peadar G.} and Knowles, {Michael R.}",
year = "2004",
month = "5",
doi = "10.1002/ppul.10448",
language = "English (US)",
volume = "37",
pages = "385--392",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Standardized Procedure for Measurement of Nasal Potential Difference

T2 - An Outcome Measure in Multicenter Cystic Fibrosis Clinical Trials

AU - Standaert, Thomas A.

AU - Boitano, Louis

AU - Emerson, Julia

AU - Milgram, Laura J H

AU - Konstan, Michael W.

AU - Hunter, Janice

AU - Berclaz, Pierre Yves

AU - Brass, Lois

AU - Zeitlin, Pamela L.

AU - Hammond, Keith

AU - Davies, Zoe

AU - Foy, Carla

AU - Noone, Peadar G.

AU - Knowles, Michael R.

PY - 2004/5

Y1 - 2004/5

N2 - Patients with cystic fibrosis (CF) can be discriminated from healthy subjects by measurement of the nasal potential difference, which has become a useful outcome measure for therapies directed toward correcting defective electrolyte transport in CF. A standard operating procedure was developed by a CF Foundation clinical trials network, to be followed by all sites performing collaborative studies. Key variables in the measurement included type of voltmeter, exploring probe, reference electrodes, and solutions used to assess both sodium transport and chloride conductance. Eight sites submitted data on 3-8 normal and 4-5 CF subjects. Baseline voltage, an index of sodium transport, was -18.2±8.3 mV (mean±SD) for normals, and -45.3 ± 11.4 mV for CF patients. There was no CFTR- mediated chloride secretion in CF subjects, as evidenced by the lack of response to perfusion with zero chloride + beta agonist solutions (+3.2 ± 3.5 mV) vs. that in normals (-23.7 ± 10.2 mV). The standardized nasal potential difference measurement minimizes variability between operators and study sites. Valid and consistent results can be attained with trained operators and attention to technical details. These data demonstrate the procedure to be sufficient for multicenter studies in the CF Foundation network.

AB - Patients with cystic fibrosis (CF) can be discriminated from healthy subjects by measurement of the nasal potential difference, which has become a useful outcome measure for therapies directed toward correcting defective electrolyte transport in CF. A standard operating procedure was developed by a CF Foundation clinical trials network, to be followed by all sites performing collaborative studies. Key variables in the measurement included type of voltmeter, exploring probe, reference electrodes, and solutions used to assess both sodium transport and chloride conductance. Eight sites submitted data on 3-8 normal and 4-5 CF subjects. Baseline voltage, an index of sodium transport, was -18.2±8.3 mV (mean±SD) for normals, and -45.3 ± 11.4 mV for CF patients. There was no CFTR- mediated chloride secretion in CF subjects, as evidenced by the lack of response to perfusion with zero chloride + beta agonist solutions (+3.2 ± 3.5 mV) vs. that in normals (-23.7 ± 10.2 mV). The standardized nasal potential difference measurement minimizes variability between operators and study sites. Valid and consistent results can be attained with trained operators and attention to technical details. These data demonstrate the procedure to be sufficient for multicenter studies in the CF Foundation network.

KW - Clinical trial

KW - Cystic fibrosis

KW - Epithelium

KW - Multicenter

KW - Nasal

KW - Potential difference

KW - SOP

UR - http://www.scopus.com/inward/record.url?scp=2442453783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442453783&partnerID=8YFLogxK

U2 - 10.1002/ppul.10448

DO - 10.1002/ppul.10448

M3 - Article

C2 - 15095320

AN - SCOPUS:2442453783

VL - 37

SP - 385

EP - 392

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 5

ER -